Axena Health's Leva® Pelvic Health System Now Available to Female Veterans Through Federal Healthcare Providers
NEWTON, Mass., May 21, 2025--(BUSINESS WIRE)--Axena Health, Inc. (Axena Health), a women's health company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive treatments, today announced female veterans now have access to the Leva Pelvic Health System through their federal healthcare providers, including the Veterans Health Administration (VHA), VA Community Care Network (CCN) and Military Health System (MHS).
"We're proud that providers at federal healthcare facilities can now prescribe the Leva Pelvic Health System as an effective, first-line treatment for urinary incontinence," said Randy Pritchard, CEO of Axena Health. "Leva enables supervised, at-home pelvic floor muscle training, giving women a convenient, and clinically proven option to manage urinary incontinence. Our modern approach is reducing barriers to care and helping more women – now including those who have served our country – access the treatment they deserve."
Up to 20 percent of female veterans experience urinary incontinence (UI), a condition that often goes untreated due to stigma and barriers to access. Many veterans face heightened risks for UI due to factors such as extended periods without urination and a history of lifting heavy protective gear. These unique challenges, combined with common risk factors like pregnancy, childbirth, and menopause, increase UI risk among female veterans.
The Leva System is designed to provide women with a convenient, non-invasive option for treating UI through a modern approach to supervised pelvic floor muscle training. The physician-prescribed program uniquely combines the FDA-cleared Leva device and smartphone app to provide at-home guided treatment, personalized coaching, educational resources, and progress tracking.
Leva is now available on the Department of Veterans Affairs' Federal Supply Schedule (FSS), GSA Advantage, and the Department of Defense's Distribution and Pricing Agreement (DAPA) through a partnership with Lovell® Government Services, a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor.
"We're proud to partner with Axena Health to advance technology that improves women's health. Enhancing care for our female veterans is incredibly important to our company," said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.
For more information about the Leva Pelvic Health System, visit levacares.com.
About Axena Health
Axena Health, Inc. is dedicated to improving the lives of women with pelvic floor disorders. Axena Health's flagship product, the Leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables a modern approach to supervised pelvic floor muscle training via precise visualization of movement in real time, while monitoring usage and progress. For more information, please visit www.axenahealth.com or www.levacares.com and follow Axena Health on LinkedIn.
About the Leva® Pelvic Health System
The Leva® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to treat urinary incontinence (UI) and chronic fecal incontinence (FI) — at home in just five minutes a day. Combining a small FDA-cleared vaginal motion sensor with integrated software, the Leva System offers precise, real-time visualization of pelvic movement, progress tracking and active physician involvement, all of which support improved treatment outcomes. The Leva System is available by prescription only, enabling physician engagement in each patient's success while also offering scalable first-line treatment of UI and chronic FI. The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).
Important Indication and Other Information for the Leva® Pelvic Health System
The Leva® Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the Leva System is by prescription and is not for everyone. Please talk to your prescriber to see if Leva System is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use Leva System while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the Leva System, see its Instructions for Use available at www.levacares.com.
About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520401137/en/
Contacts
Media: Axena Health:Makenna Lukensmlukens@vaultcommunications.com
Lovell:Jeff McKaymedia@lovellgov.com 850.912.4680
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
4 hours ago
- Yahoo
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
USA Today
6 hours ago
- USA Today
The advice you're missing about your pre-workout
Whether you're rolling out of bed at dawn, sacrificing your lunch break for gym time or syncing schedules with a motivated friend to squeeze in an evening workout, the goal is usually about making the most out of every rep, step and minute. While buying better gear, using fitness apps or hiring a personal trainer can all help, a growing number of gym goers are chasing an extra edge through supplementary pills, powders or liquids known as pre-workouts. But do these products really deliver? Here's what they are, which ingredients to watch for and what else you can do beyond supplementation to get the most out of every sweat session. What are pre-workouts? Pre-workouts are dietary supplements designed to reduce muscle fatigue and boost energy, focus, endurance and performance during exercise. Typically taken 20 to 30 minutes before training, they contain a variety of ingredients intended to prime both body and brain for more intense physical effort. Caffeine is the most common and potent ingredient in many of these products because it's a well-established stimulant that enhances alertness and reduces fatigue, at least in the short term. Most pre-workouts contain 150 to 300 milligrams (roughly the amount in 1 to 3 cups of coffee), though some provide even higher (and sometimes unsafe) doses. And while a caffeine boost helps some people, others react poorly. 'Caffeine is not for everyone,' says Bonnie Taub-Dix, a registered dietitian nutritionist and author of "Read It Before You Eat It – Taking You from Label to Table." For some, she says, "caffeine makes them feel jittery or causes an upset stomach." Beyond caffeine, other common ingredients offered in pre-workout supplements include beta-alanine and creatine, plus minerals like zinc and magnesium. Great question: What is magnesium good for? What's the best pre-workout? There's no one-size-fits-all formula since the best pre-workout supplements always depend on one's body, goals and tolerance to certain ingredients. "It's about finding what works for each individual," says Dr. Danielle Ponzio, an orthopedic surgeon who frequently treats athletes at Thomas Jefferson University Hospital in Philadelphia. Ingredients like beta-alanine and creatine are among the most well-researched and effective when properly dosed. No matter which ingredients you're eyeing, label literacy is key. 'Be sure to check labels and look for third-party tested brands to ensure safety and effectiveness,' advises Taub-Dix. That's crucial, since dietary supplements are not regulated by the U.S. Food & Drug Administration (FDA) the way food or medicine are. You'll also want to assess factors like cost, brand reputation, ingredient sourcing and overall quality in any pre-workouts you're considering. And don't overdo it with any ingredient, of course, but be especially cautious when it comes to stimulants. 'Consider how much caffeine you're actually consuming each day across all caffeinated beverages you're drinking and any supplements you're taking,' stresses Taub-Dix. The FDA recommends drinking no more than 400 milligrams daily. It's also wise to steer clear of pre-workout products with "proprietary" blends (which often obscure ingredient amounts), untested stimulants or artificial additives, as they can carry unnecessary risks. Heads up: TikTok Shop is full of supplements for sale. Nutrition experts warn to 'tread carefully.' What's the best way to prepare for a workout? Indeed, nutrition is critical for optimizing performance, regardless of which supplements you add to your diet. 'Your overall nutrition plays the most crucial role in maximizing workout performance and recovery,' says Ponzio. For example, eating a meal or snack high in carbohydrates and moderate in protein one to four hours before exercising can fuel your workout and 'optimize glycogen stores and maintain blood glucose levels,' she explains. Some balanced pre-workout snacks include Greek yogurt with fruit and nuts, oatmeal with almond butter or a smoothie made with yogurt, berries and greens, Taub-Dix says. And she cautions against relying on sugary foods or drinks, which provide only short bursts of energy and may cause digestive discomfort or sugar crashes. Similarly, consuming too much fiber right before exercise "can lead to bloating or sluggishness." Hydration is also key as replacing fluids lost through perspiration helps keep workouts safe and more effective. In the end, the most effective workout prep combines supplements (when needed), nutrition, movement and consistency, habits that pay off both before and after exercise. 'Post-exercise nutrition is also crucial,' says Ponzio. 'It can replenish glycogen stores, repair muscle tissue and rehydrate.'
